Tomoyuki Kakizume

Phase I dose‐escalation study of buparlisib (<scp>BKM</scp>120), an oral pan‐class I <scp>PI</scp>3K inhibitor, in Japanese patients with advanced solid tumors

Megumi Inada‐Inoue, Ayako Mitsuma, Takayuki Yoshino et al. · Cancer Science · 2014 · 90 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang et al. · Journal of Experimental & Clinical Cancer Research · 2022 · 77 citations · Full text

Medicine, Oncology, Pharmacology +16

Applying Meta-Analytic-Predictive Priors with the <i>R</i> Bayesian Evidence Synthesis Tools

Sebastian Weber, Yue Li, John W. Seaman et al. · Journal of Statistical Software · 2021 · 53 citations · Full text

Public Health, Biostatistics, Bayesian Biostatistics +16

Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors

Yuichi Ando, Satoru Iwasa, Shunji Takahashi et al. · Cancer Science · 2018 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors

Toshihiko Doi, Becker Hewes, Tomoyuki Kakizume et al. · Cancer Science · 2017 · 40 citations · Full text

Medicine, Oncology, Pharmacology +15